Name: Meike Kasten

Date of Birth: June 27th, 1977

Place of Birth: Herne, Germany

Position/Title: Associate Professor Neuropsychiatric Epidemiology (Department of Psychiatry and Institute of Neurogenetics), W2 Professor

Address: Department of Psychiatry and Psychotherapy and Institute of Neurogenetics, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany

Phone: +49-451-2903359; Fax: +49-451-2903355
Email: meike.kasten@neuro.uni-luebeck.de

1996-2002: University of Bochum, Germany, Medical School

2002: Medical thesis

2002-2004: Residency in Neurology, Department of Neurology, University of Lübeck

2002-present: research work in the Institute of Neurogenetics, Lübeck with Prof. Christine Klein

2004-2006: Postdoctoral Research Fellow in Neuroepidemiology at the Parkinson’s Institute in Sunnyvale, California with Prof. Caroline Tanner

2006-2011: Residency in Psychiatry, Department of Psychiatry and Psychotherapy, University of Lübeck

2011-2013: Staff Physician, Department of Psychiatry and Psychotherapy and start of the working group of Neuropsychiatric Epidemiology

2012: Habilitation

7/2013-present: W2 Professor in Neuropsychiatric Epidemiology at the Department of Psychiatry and Psychotherapy and the Institute of Neurogenetics, University of Lübeck

2018-present: After review of scientific work, permanent position as W2 Professor in Neuropsychiatric Epidemiology

2003 to present: Ad hoc reviewer for JNNP, Acta Neurologica Scandinavia, Deutsche    Medizinische Wochenschrift, and Movement Disorders

2012 to present: Editorial board of “biomedical research” and “datasets international”

2012 to present: Mentor in the Mentoring program of the German Society of Psychiatry and Psychotherapy”

2014: Member of the “Berufungskommission” Psychology

2014-to present: Mentor in the Mentoring program “women in leading positions” of the University of Lübeck

2014-to present:  Member of the “Promotionskommission” of the University of Lübeck

2004-2006: Stipend of the Michael J Fox Foundation

2005: Junior Scholarship Award of the Movement Disorder Society

2009: Travel Grant, Melvin Yahr Foundation

2011: Best Poster Awards, ‘Deutsche Gesellschaft für Neurologie’ and ‘Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde’

  1. Germer EL, Imhoff S, Vilariño-Güell C, Kasten M, Seibler P, Brüggemann N, International Parkinson’s Disease Genomics Consortium., Klein C, Trinh J. The Role of Rare Coding Variants in Parkinson’s Disease GWAS Loci. Front Neurol 2020:1284.
  2. Weissbach A, Wittke C, Kasten M, Klein C. ‘Atypical’ Parkinson’s disease – genetic. Int Rev Neurobiol 2019:207-235.
  3. Grover S, Lill CM, Kasten M, Klein C, Del Greco M F, König IR. Risky behaviors and Parkinson disease: A mendelian randomization study. Neurology 2019;15:e1412-e1424.
  4. Borsche M, Balck A, Kasten M, Lohmann K, Klein C, Brüggemann N. The sooner, the later – Delayed diagnosis in Parkinson’s disease due to Parkin mutations. Parkinsonism Relat Disord 2019:284-285.
  5. Balck A, Borsche M, Kasten M, Lohmann K, Seibler P, Brüggemann N, Klein C. Discordance in monozygotic Parkinson’s disease twins – continuum or dichotomy? Ann Clin Transl Neurol 2019;6:1102-1105.
  6. Krause C, Sievert H, Geißler C, Grohs M, El Gammal AT, Wolter S, Ohlei O, Kilpert F, Krämer UM, Kasten M, Klein C, Brabant GE, Mann O, Lehnert H, Kirchner H. Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification. Epigenomics 2019;8:885-897.
  7. Vollstedt EJ, Kasten M, Klein C, MJFF Global Genetic Parkinson’s Disease Study Group. Using global team science to identify genetic parkinson’s disease worldwide. Ann Neurol 2019;2:153-157.
  8. Olschewski L, Jesús S, Kim HJ, Tunc S, Löns S, Junker J, Zeuner KE, Kühn AA, Kuhlenbäumer G, Schäffer E, Berg D, Kasten M, Ferbert A, Altenmüller E, Brüggemann N, Bauer P, Rolfs A, Jeon B, Bäumer T, Mir P, Klein C, Lohmann K. Role of ANO3 mutations in dystonia: A large-scale mutational screening study. Parkinsonism Relat Disord 2019:196-200.
  9. Trinh J, Lohmann K, Baumann H, Balck A, Borsche M, Brüggemann N, Dure L, Dean M, Volkmann J, Tunc S, Prasuhn J, Pawlack H, Imhoff S, Lill CM, Kasten M, Bauer P, Rolfs A, International Parkinson’s Disease Genomics Consortium (IPDGC)., Klein C. Utility and implications of exome sequencing in early-onset Parkinson’s disease. Mov Disord 2018;1:133-137.
  10. Trinh J, Zeldenrust FMJ, Huang J, Kasten M, Schaake S, Petkovic S, Madoev H, Grünewald A, Almuammar S, König IR, Lill CM, Lohmann K, Klein C, Marras C. Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 2018;12:1857-1870.
  11. Heldmann M, Heeren J, Klein C, Rauch L, Hagenah J, Münte TF, Kasten M, Brüggemann N. Neuroimaging abnormalities in individuals exhibiting Parkinson’s disease risk markers. Mov Disord 2018;9:1412-1422.
  12. Mestre TA, Pont-Sunyer C, Kausar F, Visanji NP, Ghate T, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Kasten M, Wadia PM, Zadikoff C, Kumar P, de Bie RM, Thomsen T, Lang AE, Schüle B, Klein C, Tolosa E, Marras C. Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson’s disease nonparkinsonian relatives: A multicenter family study. Mov Disord 2018;6:960-965.
  13. Trinh J, Zeldenrust FMJ, Huang J, Kasten M, Schaake S, Petkovic S, Madoev H, Grünewald A, Almuammar S, König IR, Lill CM, Lohmann K, Klein C, Marras C. Genotype-phenotype relations for the Parkinson’s disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. Mov Disord 2018;12:1857-1870.
  14. Heinzel S, Kasten M, Behnke S, Vollstedt EJ, Klein C, Hagenah J, Pausch C, Heilmann R, Brockmann K, Suenkel U, Yilmaz R, Liepelt-Scarfone I, Walter U, Berg D. Age- and sex-related heterogeneity in prodromal Parkinson’s disease. Mov Disord 2018;6:1025-1027.
  15. Hebert E, Borngräber F, Schmidt A, Rakovic A, Brænne I, Weissbach A, Hampf J, Vollstedt EJ, Größer L, Schaake S, Müller M, Manzoor H, Jabusch HC, Alvarez-Fischer D, Kasten M, Kostic VS, Gasser T, Zeuner KE, Kim HJ, Jeon B, Bauer P, Altenmüller E, Klein C, Lohmann K. Functional Characterization of Rare RAB12 Variants and Their Role in Musician’s and Other Dystonias. Genes (Basel) 2017;10
  16. Shamir R, Klein C, Amar D, Vollstedt EJ, Bonin M, Usenovic M, Wong YC, Maver A, Poths S, Safer H, Corvol JC, Lesage S, Lavi O, Deuschl G, Kuhlenbaeumer G, Pawlack H, Ulitsky I, Kasten M, Riess O, Brice A, Peterlin B, Krainc D. Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology 2017;16:1676-1683.
  17. Kasten M, Marras C, Klein C. Nonmotor Signs in Genetic Forms of Parkinson’s Disease. Int Rev Neurobiol 2017:129-178.
  18. Weissbach A, König IR, Hückelheim K, Pramstaller PP, Werner E, Brüggemann N, Tadic V, Lohmann K, Bäumer T, Münchau A, Kasten M, Klein C. Influence of L-dopa on subtle motor signs in heterozygous Parkin- and PINK1 mutation carriers. Parkinsonism Relat Disord 2017:95-99.
  19. Steinlechner S, Hagenah J, Rumpf HJ, Meyer C, John U, Bäumer T, Brüggemann N, Kasten M, Münchau A, Klein C, Lencer R. Associations of specific psychiatric disorders with isolated focal dystonia, and monogenic and idiopathic Parkinson’s disease. J Neurol 2017;6:1076-1084.
  20. Prasuhn J, Piskol L, Vollstedt EJ, Graf J, Schmidt A, Tadic V, Tunc S, Hampf J, Warrlich E, Bibergeil C, Hagenah J, Klein C, Kasten M, Brüggemann N. Non-motor symptoms and quality of life in subjects with mild parkinsonian signs. Acta Neurol Scand 2017;5:495-500.
  21. Markopoulou K, Chase BA, Robowski P, Strongosky A, Narożańska E, Sitek EJ, Berdynski M, Barcikowska M, Baker MC, Rademakers R, Sławek J, Klein C, Hückelheim K, Kasten M, Wszolek ZK. Assessment of Olfactory Function in MAPT-Associated Neurodegenerative Disease Reveals Odor-Identification Irreproducibility as a Non-Disease-Specific, General Characteristic of Olfactory Dysfunction. PLoS One 2016;11:e0165112.
  22. Lawton M, Kasten M, May MT, Mollenhauer B, Schaumburg M, Liepelt-Scarfone I, Maetzler W, Vollstedt EJ, Hu MT, Berg D, Ben-Shlomo Y. Validation of conversion between mini-mental state examination and montreal cognitive assessment. Mov Disord 2016;4:593-596.
  23. Koschmidder E, Weissbach A, Brüggemann N, Kasten M, Klein C, Lohmann K. A nonsense mutation in CHCHD2 in a patient with Parkinson disease. Neurology 2016;6:577-579.
  24. Kritzinger C, Vollstedt EJ, Hückelheim K, Lorwin A, Graf J, Tunc S, Klein C, Kasten M. Qualitative Characteristics of Depression in Parkinson’s Patients and Controls. Behav Neurol 2015:961372.
  25. Kasten M, Klein C. Genetic risk loci for Parkinson’s disease: Moving from state to trait? Mov Disord 2015;6:747-749.
  26. Tadic V, Westenberger A, Domingo A, Alvarez-Fischer D, Klein C, Kasten M. Primary familial brain calcification with known gene mutations: a systematic review and challenges of phenotypic characterization. JAMA Neurol 2015;4:460-467.
  27. Tunc S, Graf J, Tadic V, Brüggemann N, Schmidt A, Al-Khaled M, Wolff S, Vollstedt EJ, Lorwin A, Hampf J, Piskol L, Klein C, Hagenah J, Kasten M. A population-based study on combined markers for early Parkinson’s disease. Mov Disord 2014;4:531-537.
  28. Winkler S, Vollstedt EJ, Kasten M, Alvarez-Fischer D, Klein C, Lohmann K. The recurrent mutation Arg258Gln in SYNJ1 (PARK20) is not a common cause of Parkinson’s disease. J Neurol 2014;4:833-834.
  29. Kumar KR, Lohmann K, Masuho I, Miyamoto R, Ferbert A, Lohnau T, Kasten M, Hagenah J, Brüggemann N, Graf J, Münchau A, Kostic VS, Sue CM, Domingo AR, Rosales RL, Lee LV, Freimann K, Westenberger A, Mukai Y, Kawarai T, Kaji R, Klein C, Martemyanov KA, Schmidt A. Mutations in GNAL: a novel cause of craniocervical dystonia. JAMA Neurol 2014;4:490-494.
  30. Brüggemann N, Stiller S, Tadic V, Kasten M, Münchau A, Graf J, Klein C, Hagenah J. Non-motor phenotype of dopa-responsive dystonia and quality of life assessment. Parkinsonism Relat Disord 2014;4:428-431.
  31. Koschmidder E, Mollenhauer B, Kasten M, Klein C, Lohmann K. Mutations in VPS26A are not a frequent cause of Parkinson’s disease. Neurobiol Aging 2014;6:1512.e1-2.
  32. Lohmann K, Schmidt A, Schillert A, Winkler S, Albanese A, Baas F, Bentivoglio AR, Borngräber F, Brüggemann N, Defazio G, Del Sorbo F, Deuschl G, Edwards MJ, Gasser T, Gómez-Garre P, Graf J, Groen JL, Grünewald A, Hagenah J, Hemmelmann C, Jabusch HC, Kaji R, Kasten M, Kawakami H, Kostic VS, Liguori M, Mir P, Münchau A, Ricchiuti F, Schreiber S, Siegesmund K, Svetel M, Tijssen MA, Valente EM, Westenberger A, Zeuner KE, Zittel S, Altenmüller E, Ziegler A, Klein C. Genome-wide association study in musician’s dystonia: a risk variant at the arylsulfatase G locus? Mov Disord 2013;7:921-927.
  33. Kasten M, Grünewald A, Klein C. Next-generation phenotyping and genomic incidental findings–reply. JAMA Neurol 2013;12:1590-1591.
  34. Schmidt A, Jabusch HC, Altenmüller E, Kasten M, Klein C. Challenges of making music: what causes musician’s dystonia? JAMA Neurol 2013;11:1456-1459.
  35. Doss S, Lohmann K, Seibler P, Arns B, Klopstock T, Zühlke C, Freimann K, Winkler S, Lohnau T, Drungowski M, Nürnberg P, Wiegers K, Lohmann E, Naz S, Kasten M, Bohner G, Ramirez A, Endres M, Klein C. Recessive dystonia-ataxia syndrome in a Turkish family caused by a COX20 (FAM36A) mutation. J Neurol 2013;1:207-212.
  36. Grünewald A, Kasten M, Ziegler A, Klein C. Next-generation phenotyping using the parkin example: time to catch up with genetics. JAMA Neurol 2013;9:1186-1191.
  37. Kasten M, Heinzow B, Vieregge P, Klein C. Reply to: “polychlorinated biphenyls in prospectively collected serum and Parkinson’s disease risk”. Mov Disord 2013;9:1317.
  38. Kasten M, Klein C. The many faces of alpha-synuclein mutations. Mov Disord 2013;6:697-701.
  39. Lohmann K, Wilcox RA, Winkler S, Ramirez A, Rakovic A, Park JS, Arns B, Lohnau T, Groen J, Kasten M, Brüggemann N, Hagenah J, Schmidt A, Kaiser FJ, Kumar KR, Zschiedrich K, Alvarez-Fischer D, Altenmüller E, Ferbert A, Lang AE, Münchau A, Kostic V, Simonyan K, Agzarian M, Ozelius LJ, Langeveld AP, Sue CM, Tijssen MA, Klein C. Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol 2013;4:537-545.
  40. Appenzeller S, Schulte C, Thier S, Hopfner F, Pendziwiat M, Papengut F, Klein C, Hagenah J, Kasten M, Srulijes K, Berg D, Gasser T, Singleton A, Deuschl G, Kuhlenbäumer G. No association between polymorphisms in the glutamate transporter SLC1A2 and Parkinson’s disease. Mov Disord 2013;9:1305-1306.
  41. Weissbach A, Kasten M, Grünewald A, Brüggemann N, Trillenberg P, Klein C, Hagenah J. Prominent psychiatric comorbidity in the dominantly inherited movement disorder myoclonus-dystonia. Parkinsonism Relat Disord 2013;4:422-425.
  42. Lohmann K, Schmidt A, Schillert A, Winkler S, Albanese A, Baas F, Bentivoglio AR, Borngräber F, Brüggemann N, Defazio G, Del Sorbo F, Deuschl G, Edwards MJ, Gasser T, Gómez-Garre P, Graf J, Groen JL, Grünewald A, Hagenah J, Hemmelmann C, Jabusch HC, Kaji R, Kasten M, Kawakami H, Kostic VS, Liguori M, Mir P, Münchau A, Ricchiuti F, Schreiber S, Siegesmund K, Svetel M, Tijssen MA, Valente EM, Westenberger A, Zeuner KE, Zittel S, Altenmüller E, Ziegler A, Klein C. Genome-wide association study in musician’s dystonia: a risk variant at the arylsulfatase G locus? Mov Disord 2013;7:921-927.
  43. Kasten M, Hagenah J, Graf J, Lorwin A, Vollstedt EJ, Peters E, Katalinic A, Raspe H, Klein C. Cohort Profile: a population-based cohort to study non-motor symptoms in parkinsonism (EPIPARK). Int J Epidemiol 2012;1:128-128k.
  44. Weissbach A, Siegesmund K, Brüggemann N, Schmidt A, Kasten M, Pichler I, Muhle H, Lohmann E, Lohnau T, Schwinger E, Hagenah J, Stephani U, Pramstaller PP, Klein C, Lohmann K. Exome sequencing in a family with restless legs syndrome. Mov Disord 2012;13:1686-1689.
  45. Schneider SA, Drude L, Kasten M, Klein C, Hagenah J. A study of subtle motor signs in early Parkinson’s disease. Mov Disord 2012;12:1563-1566.
  46. Tadic V, Kasten M, Brüggemann N, Stiller S, Hagenah J, Klein C. Dopa-responsive dystonia revisited: diagnostic delay, residual signs, and nonmotor signs. Arch Neurol 2012;12:1558-1562.
  47. Appenzeller S, Thier S, Papengut F, Klein C, Hagenah J, Kasten M, Berg D, Srulijes K, Gasser T, Schreiber S, Deuschl G, Kuhlenbäumer G. No association between NOD2 variants and Parkinson’s disease. Mov Disord 2012;9:1191-1192.
  48. Kumar KR, Weissbach A, Heldmann M, Kasten M, Tunc S, Sue CM, Svetel M, Kostić VS, Segura-Aguilar J, Ramirez A, Simon DK, Vieregge P, Münte TF, Hagenah J, Klein C, Lohmann K. Frequency of the D620N mutation in VPS35 in Parkinson disease. Arch Neurol 2012;10:1360-1364.
  49. Kasten M, Kertelge L, Tadic V, Brüggemann N, Schmidt A, van der Vegt J, Siebner H, Buhmann C, Lencer R, Kumar KR, Lohmann K, Hagenah J, Klein C. Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson’s disease. Mov Disord 2012;6:754-759.
  50. Kasten M, Brüggemann N, König IR, Doerry K, Steinlechner S, Wenzel L, Lohmann K, Klein C, Lencer R. Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology (Berl) 2010;3:729-736.
  51. Brüggemann N, Hagenah J, Reetz K, Schmidt A, Kasten M, Buchmann I, Eckerle S, Bähre M, Münchau A, Djarmati A, van der Vegt J, Siebner H, Binkofski F, Ramirez A, Behrens MI, Klein C. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010;11:1357-1363.
  52. Grünewald A, Voges L, Rakovic A, Kasten M, Vandebona H, Hemmelmann C, Lohmann K, Orolicki S, Ramirez A, Schapira AH, Pramstaller PP, Sue CM, Klein C. Mutant Parkin impairs mitochondrial function and morphology in human fibroblasts. PLoS One 2010;9:e12962.
  53. Kertelge L, Brüggemann N, Schmidt A, Tadic V, Wisse C, Dankert S, Drude L, van der Vegt J, Siebner H, Pawlack H, Pramstaller PP, Behrens MI, Ramirez A, Reichel D, Buhmann C, Hagenah J, Klein C, Lohmann K, Kasten M. Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson’s disease. Mov Disord 2010;15:2665-2669.
  54. Zittel S, Moll CK, Brüggemann N, Tadic V, Hamel W, Kasten M, Lohmann K, Lohnau T, Winkler S, Gerloff C, Schönweiler R, Hagenah J, Klein C, Münchau A, Schneider SA. Clinical neuroimaging and electrophysiological assessment of three DYT6 dystonia families. Mov Disord 2010;14:2405-2412.
  55. Kasten M, Bruggemann N, Schmidt A, Klein C. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2010;5:478; author reply 478-9.
  56. Reetz K, Tadic V, Kasten M, Brüggemann N, Schmidt A, Hagenah J, Pramstaller PP, Ramirez A, Behrens MI, Siebner HR, Klein C, Binkofski F. Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiol Dis 2010;3:402-408.
  57. Kasten M, Tadic V, Klein C, Rocca WA, Savica R, Eric Ahlskog J, Grossardt BR. Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology 2010;20:1655; author reply 1655-6.
  58. Klebe S, Thier S, Lorenz D, Nothnagel M, Schreiber S, Klein C, Hagenah J, Kasten M, Berg D, Srulijes K, Gasser T, Deuschl G, Kuhlenbäumer G. LINGO1 is not associated with Parkinson’s disease in German patients. Am J Med Genet B Neuropsychiatr Genet 2010;6:1173-1178.
  59. Kasten M, Weichert C, Lohmann K, Klein C. Clinical and demographic characteristics of PINK1 mutation carriers–a meta-analysis. Mov Disord 2010;7:952-954.
  60. Zschiedrich K, König IR, Brüggemann N, Kock N, Kasten M, Leenders KL, Kostić V, Vieregge P, Ziegler A, Klein C, Lohmann K. MDR1 variants and risk of Parkinson disease. Association with pesticide exposure? J Neurol 2009;1:115-120.
  61. Hagenah JM, König IR, Becker B, Hilker R, Kasten M, Hedrich K, Pramstaller PP, Klein C, Seidel G. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007;10:1407-1413.
  62. Hedrich K, Winkler S, Hagenah J, Kabakci K, Kasten M, Schwinger E, Volkmann J, Pramstaller PP, Kostic V, Vieregge P, Klein C. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson’s disease. Mov Disord 2006;9:1506-1510.
  63. Buhmann C, Binkofski F, Klein C, Büchel C, van Eimeren T, Erdmann C, Hedrich K, Kasten M, Hagenah J, Deuschl G, Pramstaller PP, Siebner HR. Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain 2005;Pt 10:2281-2290.
  64. Hedrich K, Pramstaller PP, Stübke K, Hiller A, Kabakci K, Purmann S, Kasten M, Scaglione C, Schwinger E, Volkmann J, Kostic V, Vieregge P, Martinelli P, Abbruzzese G, Klein C, Zühlke C. Premutations in the FMR1 gene as a modifying factor in Parkin-associated Parkinson’s disease? Mov Disord 2005;8:1060-1062.
  65. Lencer R, Eismann G, Kasten M, Kabakci K, Geithe V, Grimm J, Klein C. Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms. Br J Psychiatry 2004:465-471.
  66. Kock N, Kasten M, Schüle B, Hedrich K, Wiegers K, Kabakci K, Hagenah J, Pramstaller PP, Nitschke MF, Münchau A, Sperner J, Klein C. Clinical and genetic features of myoclonus-dystonia in 3 cases: a video presentation. Mov Disord 2004;2:231-234.
  67. Wellenbrock C, Hedrich K, Schäfer N, Kasten M, Jacobs H, Schwinger E, Hagenah J, Pramstaller PP, Vieregge P, Klein C. NR4A2 mutations are rare among European patients with familial Parkinson’s disease. Ann Neurol 2003;3:415.